

Characteristics of Fluoroquinolone-Resistant of Avian Pathogenic *Escherichia coli* Isolates in China

^{1,2}Xiaowen Liu, ²Yanhong Wang and ^{1,2}Xiaoquan Wang

¹Key Laboratory of Animal Infectious Diseases, Ministry of Agriculture,

²Ministry of Education Key Lab for Avian Preventive Medicine, School of Veterinary Medicine, Yangzhou University, Yangzhou, 225009 Jiangsu, China

Abstract: A total of 121 Avian Pathogenic *Escherichia coli* (APEC) isolates recovered from diagnosed cases of avian colibacillosis from China during 2009 and 2011 were serotyped and examined for susceptibility to nalidixic acid and 6 fluoroquinolones. About 23 different serotypes were determined by agglutination using antisera and O78 (28/121), O143 (21/121) and O2 (15/121) were predominant serotypes. APEC isolates displayed resistance to nalidixic acid (95.9%), norfloxacin (95.0%), ciprofloxacin (94.2%), enrofloxacin (86.8%), levofloxacin (75.2%), lomefloxacin (63.6%) and ofloxacin (61.2%), respectively. Single gyrA changes (mainly Ser 83 to Leu) correlated with nalidixic acid MICs $\geq 32 \mu\text{g mL}^{-1}$. The Asp87 changes (mainly Asp87 to Asn) in gyrA were associated with higher ciprofloxacin MICs. ParC alterations comprised amino acid changes Ser 80 to Ile, Ser 80 to Arg, Glu84 to Gly, Glu84 to Lys. The fluoroquinolone-resistant strains for which nalidixic acid MICs were $>256 \mu\text{g mL}^{-1}$ had both gyrA and parC QRDR point mutations. The fluoroquinolone-resistant isolates had common point mutations in gyrA (Ser 83 to Leu, Asp87 to Asn) and parC (Ser80 to Ile). These strains for which ciprofloxacin MICs were $>8 \mu\text{g mL}^{-1}$ had double gyrA mutations, accompanying with ParC alterations. Seven recent isolates carried *qnrS* gene and three carried *aac(6)-Ib-cr* gene. This suggests that the widespread mutations at position 83, 87 of gyrA and position 80 of parC were crucial for resistance to fluoroquinolone and showed significant relation to the high-level fluoroquinolone resistance in APEC.

Key words: Fluoroquinolone, resistant, avian pathogenic *Escherichia coli*, nalidixic acid, China

INTRODUCTION

Avian Pathogenic *Escherichia coli* (APEC) belongs to the extra-intestinal pathogenic group of *E. coli*. These bacteria cause several severe disease syndromes in farmed birds such as peritonitis, enteritis, air sac disease, pericarditis, perihepatitis, salpingitis, synovitis, panophthalmitis in poultry (Gross, 1994). APEC has been known to cause disease among chickens and other fowls which usually results in large economic losses for the poultry industry (Antao *et al.*, 2009), its strains belong predominantly to three serogroups, O1, O2 and O78 in China.

Research on APEC has increased greatly over the years where the susceptibility of the pathogen to those antimicrobial agents commonly used for treatment such as fluoroquinolones is decreasing (Gomis *et al.*, 2003). APEC are mostly associated with infection of extraintestinal tissues in chickens, turkeys, ducks and other avian species. The most important disease syndrome associated with APEC begins as a respiratory tract

infection and may be aerosacculitis or the air sac disease (Dho-Moulin and Fairbrother, 1999). This inevitably results in severe systemic infection leading to death of the animal infected. APEC have recently been classified under the category of Extraintestinal Pathogenic *E. coli* (ExPEC), a group which includes human pathogens like the Uropathogenic *E. coli* (UPEC), Newborn Meningitic *E. coli* (NMEC) and animal pathogens which in turn suggest APEC have the possibility of zoonotic potential (Antao *et al.*, 2009; Ewers *et al.*, 2007; Johnson *et al.*, 2003; Kariyawasam *et al.*, 2007).

Fluoroquinolones are considered the drug of choice for the treatment of *E. coli* infections of human (Noguera *et al.*, 2011; Obeng *et al.*, 2012; Yasufuku *et al.*, 2011) and the recently observed increase in the number of Fluoroquinolone-resistant strains is an alarming public health concern (Karaca *et al.*, 2005). Fluoroquinolones are also widely used in farm animals, mainly in poultry and Fluoroquinolone-resistant *E. coli* strains are frequently isolated from healthy and diseased birds in China and other country (McPeake *et al.*, 2005;

Zhao *et al.*, 2005). Therefore, resistance to fluoroquinolones in *E. coli* has increased due to their large use. Fluoroquinolones resistance involves three main mechanisms: target mutations, reduced antibiotic intracellular accumulation by lowering outer membrane permeability or increasing efflux activity (Swick *et al.*, 2011) and target protection mediated by the *qnr* protein (Martinez-Martinez *et al.*, 1998). Among them, clinical resistance to quinolones in *E. coli* is mostly associated with mutations in genes that encode subunits of the quinolone target DNA gyrase and topoisomerase IV (Yoshida *et al.*, 1988). More recently, plasmid-mediated mechanisms were reported such as those due to *qnr* genes encoding pentapeptide repeat proteins, *aac(6)-Ib-cr* encoding a modified acetyltransferase (Warburg *et al.*, 2009) and *qepA* encoding an active efflux pump. *qnr* and *aac(6)-Ib-cr* genes confer reduced quinolone susceptibility, facilitating the selection of chromosomal mutations that confer high-level resistance (George *et al.*, 2006; Liu *et al.*, 2012a, b; Vasilaki *et al.*, 2008). Fluoroquinolone resistance in *E. coli* appeared to be a stepwise phenomenon with MIC increasing as the number of point mutations in *gyrA* increased but high-level resistance and multidrug resistance associated with fluoroquinolone resistance reflected overexpression of the AcrAB efflux pump (Shaheen *et al.*, 2011). In fluoroquinolone-resistant isolates, DNA gyrase, the primary target in Gram-negative bacteria, commonly presents substitutions at amino acid position Ser83 and/or Asp87 of the *gyrA* subunit while substitutions at residues Ser80 and Glu84 are commonly identified alterations in the *parC* subunit of the topoisomerase IV (Karcznarczyk *et al.*, 2011; Li *et al.*, 1998).

MATERIALS AND METHODS

Isolation and identification of avian *E. coli* strains: A total of 121 (31 isolated in 2009, 28 in 2010, 33 in 2011 and 29 in 2012) avian *E. coli* strains were isolated from poultry outbreaks of APEC infections occurring during 2009-2012 in free-range poultry farm or intensive farming units in eastern China. Bacteria from diseased animals were isolated from necropsy specimens and cultured on 5% sheep blood and MacConkey agar. The isolates were serotyped at the Key Laboratory of Animal Infectious Diseases of Ministry of Agriculture located at Yangzhou University. Serotyping was performed by agglutination using antisera for 181 somatic O types (Orskov and Orskov, 1990). *E. coli* strains were stored in tryptone soy broth (Oxoid, Hampshire, UK) with 15% glycerol at -70°C.

Fluoroquinolones susceptibility testing: For nalidixic acid, the susceptibility determination was performed by a

Broth Microdilution Method and according to the breakpoints defined by the Clinical and Laboratory Standards Institute (CLSI), resistance was defined as isolates having a Minimal Inhibitory Concentration (MIC) $\geq 32 \mu\text{g mL}^{-1}$.

The MICs of ciprofloxacin, ofloxacin, norfloxacin (Sigma Chemical, MO, USA), levofloxacin, enrofloxacin and lomefloxacin (Sangon, Shanghai, China) were determined against 121 APEC isolates by the Agar Dilution Method according to CLSI guidelines using Mueller-Hinton agar as a culture medium. The range of concentrations evaluated was 0.5-512 $\mu\text{g mL}^{-1}$ for all the fluoroquinolones tested. *Escherichia coli* ATCC 25922 was included as control strain.

Mutational analysis of QRDRs in *gyrA*, *gyrB* and *parC*:

A total of 24 strains of fluoroquinolone-resistant APEC, together with 4 strains of APEC that were susceptible to fluoroquinolones (ciprofloxacin and levofloxacin), 4 susceptible to nalidixic acid were grown in Luria Bertani (LB) medium. Their genomic DNA was extracted and used as a template. The QRDRs of *gyrA*, *gyrB* and *parC* were amplified by PCR using earlier published primers (Everett *et al.*, 1996; Sorlozano *et al.*, 2007; Vila *et al.*, 1996; Zhao *et al.*, 2005). The PCR was performed in a 25 μL reaction mixture that contained 2 μL DNA template, 4 pmol (each) primer, 0.2 mM (each) deoxynucleoside triphosphate, 2.5 μL 10x PCR buffer with 15 mM MgCl_2 and 1 U Taq DNA Polymerase (Promega, USA). The reaction was carried out in the PTC-0200G DNA Engine Thermal Cycler (Bio Rad) with the following schedule: preheating at 94°C for 2 min followed by 30 cycles of denaturation at 94°C for 30 sec, annealing at 59°C for 30 sec and extension at 72°C for 50 sec with a final extension at 72°C for 7 min. The PCR products were electrophoresed in 2% agarose gels stained with ethidium bromide and certificated under UV transillumination. The PCR products were purified using the MinElute PCR Purification kit (QIAGEN, Valencia, CA, USA) and sequenced by the Applied Biosystems 3730 DNA analyzer at Sangon biotech (Shanghai) Co., Ltd. Pairwise alignments of DNA sequences were carried out using the BLAST server of the National Center for Biotechnology Information.

RESULTS

Serotyping: About 121 APEC strains were serotyped with antisera specific for 181 somatic O types. Serotype O78 was the most frequently observed (23.1%, 28/121) followed by O143 (17.4%, 21/121), O2 (12.4%, 15/121), O127 (8.3%, 10/121), O1 (7.4%, 9/121), O18 (5.8%, 7/121), O15 (4.1%, 5/121), O11 (3.3%, 4/121), O109 (3%, 3/121), O4,

Table 1: Serotype identification of avian pathogenic *Escherichia coli* from the Eastern China

Serotypes	No. of strains (%)	Serotype	No. of strains (%)
O78	28 (23.1)	O8	2 (1.7)
O143	21 (17.4)	O6	2 (1.7)
O2	15 (12.4)	O17	2 (1.7)
O127	10 (8.30)	O9	2 (1.7)
O1	9 (7.400)	O88	1 (0.8)
O18	7 (5.800)	O96	1 (0.8)
O15	5 (4.100)	O152	1 (0.8)
O11	4 (3.300)	O20	1 (0.8)
O109	3 (2.500)	O21	1 (0.8)
O4	2 (1.700)	O27	1 (0.8)
O22	2 (1.700)	O160	1 (0.8)

O22, O8, O6, O17, O9 (1.7%, 2/121) and O88, O96, O152, O20, O21, O27, O160 (0.8%, 1/121). Information on the APEC strains examined in this study is given in Table 1.

Fluoroquinolones susceptibility: During the 4 years study period, resistance to nalidixic acid, norfloxacin, ciprofloxacin, enrofloxacin, levofloxacin, lomefloxacin and ofloxacin was found in APEC at rates of 95.9, 95.0, 94.2, 86.8, 75.2, 63.6 and 61.2%, respectively (Table 2). Resistance to nalidixic acid was detected in 100% of the APEC isolates since 2010. Percentages of resistance to antibiotics are presented by year in Fig. 1. Among APEC isolates consistently high rates of norfloxacin and ciprofloxacin resistance were detected during the study period ranging from 80.6% in 2009 to 100% in 2012 and from 83.9% in 2009 to 100% in 2012. Furthermore, resistance rates to fluoroquinolone tested remained high (>60%) during the survey and had an increasing trend.

The >50% of APEC isolates exhibited resistance to all six fluoroquinolones tested. MIC50 and MIC90 values were higher for the APEC isolates as compared to the data reported in other country (Lo *et al.*, 2011). At a concentration of 8 µg mL⁻¹ or higher, >50% of the *E. coli* isolates were inhibited by levofloxacin, enrofloxacin, lomefloxacin, ofloxacin and norfloxacin. The MIC of nalidixic acid of the inherently ciprofloxacin-resistant strain (e.g., D2 strain) was also determined and an even higher level of resistance was observed (MIC ≥512 µg mL⁻¹). In strains that gained high-level resistance to ciprofloxacin (MIC ≥8 µg mL⁻¹) the nalidixic acid resistance also increased (MIC ≥512 µg mL⁻¹) (Table 3). Two of the veterinary fluoroquinolones, norfloxacin and enrofloxacin, possessed identical MIC50 and MIC90 values of 16 and 64 µg mL⁻¹, respectively. The greatest MIC90 for the fluoroquinolones was observed with ciprofloxacin (128 µg mL⁻¹) whereas levofloxacin and lomefloxacin exhibited the lowest MIC90, 16 µg mL⁻¹ (Table 2).

Mutations in the QRDRs of fluoroquinolone-resistant APEC isolates: Researchers selected 28 isolates for

Table 2: *In vitro* activities of avian pathogenic *E. coli* recovered from diseased poultry (n = 121)

Antibiotic	MIC (µg mL ⁻¹)				Susceptibility ^a (n = 121)	
	Resistant breakpoint	Range	MIC50 ^b	MIC90 ^c	S%	R%
Nalidixic acid	≥32	32 to >512	128	>512	0	95.9
Norfloxacin	≥16	1-128	16	64	3	95.0
Ciprofloxacin	≥4	0.5-128	8	64	0	94.2
Enrofloxacin	≥8	≤0.5-64	16	64	11	86.8
Levofloxacin	≥8	≤0.5-16	8	16	20	75.2
Lomefloxacin	≥8	≤0.5-32	8	16	31	63.6
Ofloxacin	≥8	≤0.5-32	8	32	27	61.2

^aS: Susceptible; R: Resistant, MICs determined via broth Micro-Dilution Methods in accordance CLSI standards (CLSI in 2007); ^bThe MIC at which 50% of the isolates are inhibited; ^cThe MIC at which 90% of the isolates are inhibited




Fig. 1: Trend of selected APEC isolates resistant to quinolone in China from 2009-2012

molecular characterization of *gyrA*, *gyrB*, *parC*, *qnrS* and *aac(6)-Ib-cr* genes. Of these, 22 out of 28 isolates with ciprofloxacin MIC ≥4 µg mL⁻¹ and 6 out of 28 isolates with MIC ≤2 µg mL⁻¹ were successfully sequenced. As shown in Table 3, 28 isolates contained at least one mutation in *gyrA*, 22 isolates contained double mutations in *gyrA*, 21 isolates contained at least one mutation in *parC* and 21 isolates contained at least one mutation in *parC* and double mutations in *gyrA*. Among isolates containing mutations in both *parC* and *gyrA* all were resistant to ciprofloxacin with MIC ≥8 µg mL⁻¹ (Table 3).

An amino acid replacement in the QRDR of *gyrA* (Ser-83→Leu) was predicted for all the nalidixic acid-resistant isolates. About 23 isolates with nalidixic acid MIC ≥128 µg mL⁻¹ and resistant to ciprofloxacin possessed double point mutations in *gyrA*, Ser-83→Leu and Asp-87→Asn. It was predicted the replacements of Ser-83→Leu and Asp-87→Asn in *gyrA* of ciprofloxacin-resistant isolates was the principal replacement (23 of 23 isolates; 100%) while other substitutions were rare. In *gyrB*, researchers found changes of Asp-96 to Glu in 1 isolate, Ala-97 to Pro in 1 isolate and to Phe in 1 isolate and Ser-491 to Asn in 1 isolate.

Table 3: Characteristics for the fluoroquinolone-resistant isolates

Strains	Serotype	Years	MIC ($\mu\text{g mL}^{-1}$)			Mutations in the QRDRs						
						gyrA				parC		
			NAL ^a	CIP	NOR	83	87	gyrB	80	84	qnrS	aac(6)-Ib-cr
C1	O2	2009	>512	8.0	16	S ^b -L	D-N	-	S-I	-	-	-
C5	O2	2010	>512	16.0	16	S-L	D-N	-	S-I	-	-	-
D2	O2	2011	>512	64.0	128	S-L	D-N	-	S-I	-	+	-
C10	O2	2012	>512	8.0	128	S-L	D-N	D96E	S-I	-	+	+
G1	O78	2009	>512	16.0	128	S-L	D-N	-	S-I	-	-	-
C12	O78	2010	>512	32.0	128	S-L	D-N	-	S-I	-	+	-
C3	O78	2011	>512	32.0	128	S-L	D-N	-	S-I	-	+	-
C8	O78	2012	>512	64.0	32	S-L	D-N	-	S-I	-	+	-
D13	O143	2009	512	8.0	128	S-L	D-N	-	S-I	E-G	-	-
C11	O143	2010	>512	16.0	128	S-L	D-N	-	S-I	-	-	-
C20	O143	2011	>512	8.0	64	S-T	D-N	-	S-I	-	-	-
C9-3	O143	2012	512	8.0	64	S-L	D-N	-	S-I	-	+	-
D8-1	O127	2009	512	8.0	64	S-L	D-N	A97P	S-I	-	-	-
C28	O127	2011	>512	16.0	32	S-L	D-N	-	S-I	-	-	-
C30	O1	2009	>512	16.0	32	S-L	D-N	-	S-I	-	-	-
D7-4	O1	2010	>512	64.0	64	S-L	D-N	-	S-I	E-K	-	+
G3b	O1	2011	256	8.0	64	S-L	D-N	-	S-R	-	-	-
C21-2	O1	2012	512	64.0	128	S-L	D-N	-	S-I	-	+	+
D9d	O15	2009	512	16.0	32	S-L	D-N	-	S-I	-	-	-
C91	O18	2012	>512	64.0	16	S-L	D-N	S491N	S-I	-	-	-
C33	O11	2010	>512	64.0	8	S-L	D-N	-	S-I	-	-	-
C99	O11	2012	256	4.0	8	S-L	-	-	S-I	-	-	-
D3a	O109	2009	128	4.0	8	S-L	D-N	-	-	E-G	-	-
C4f	O4	2010	64	1.0	4	S-L	-	-	-	-	-	-
C41	O22	2012	64	0.5	2	S-L	-	-	-	-	-	-
G56	O6	2011	32	1.0	8	S-L	-	-	-	-	-	-
D17	O8	2009	32	1.0	4	S-L	-	-	-	-	-	-
C73	O9	2012	32	1.0	2	S-L	-	-	-	-	-	-
G95c	O20	2010	32	0.5	1	S-L	-	-	-	-	-	-

^aNAL: Nalidixic Acid; CIP: Ciprofloxacin; NOR: Norfloxacin. ^bS: Ser; L: Leu; D: Asp; N: Asn; Y: Tyr; P: Pro; A: Ala; I: Ile; R: Arg; K: Lys; G: Gly

The amino acid sequences in the QRDR of parC showed a high frequency of replacement of Ser-80 to Ile (22 isolates) or Arg (1 isolates) while other replacements were rare. It is notable that all of the isolates with mutation in parC had a mutation in gyrA. Thus, it was confirmed that alterations in parC occurred at a second step in strains already having a single alteration in gyrA in *E. coli*. Moreover, strains with two alterations (Ser-83→Leu in gyrA plus Ser-80→Ile in parC) were most frequently identified in clinical isolates (22 isolates). All nalidixic acid-resistant isolates for which MICs of nalidixic acid were $\geq 512 \mu\text{g mL}^{-1}$ and MIC of ciprofloxacin $\geq 4 \mu\text{g mL}^{-1}$ had substitutions in both QRDRs of gyrA and parC. The ParC alterations were seen in these isolates only in the presence of gyrA changes. Among ciprofloxacin-resistant strains it was found that seven recent isolates carried *qnrS* gene and three carried *aac(6)-Ib-cr* gene.

DISCUSSION

Avian pathogenic *E. coli* is an economically important pathogen of chickens worldwide and is responsible for increased mortalities in poultry flocks.

Worldwide, including China, Korea, Japan, avian pathogenic *E. coli* strains commonly belong to certain serogroups, O78, O2 and O1 and to a restricted number of clones (Dho-Moulin and Fairbrother, 1999; Jeong *et al.*, 2012; Wang *et al.*, 2010). The frequencies of these serogroups among APEC isolates vary according to location and host. In this study, serotyping revealed that about 43% of the strains belonged to these three serogroups. However, >50% of APEC isolates (O143, 21/121) could not be assigned to the serogroups indicating that a great variety of *E. coli* serogroups can be widespread in China.

The prevalence of fluoroquinolone resistance among APEC increased following the introduction of norfloxacin, ciprofloxacin and enrofloxacin into the veterinary use since 1990s. Resistance in *E. coli* to the fluoroquinolone has caused their use to decline in the treatment of colibacillosis (Boyd *et al.*, 2008). Fluoroquinolone use and resistance to fluoroquinolones are increasing. In the study, in the past 10 years, resistance to fluoroquinolone such as ofloxacin and lomefloxacin was present in more than half of *E. coli* isolates, representing about 40% increase in resistance since 2009 and continuing the concerning trend noted during that period.

The present study demonstrates that high-level fluoroquinolone resistance is a multifactorial process and that the most resistant isolates (nalidixic acid MICs $\geq 256 \mu\text{g mL}^{-1}$) usually possess at least two mutations within target genes and the isolates (ciprofloxacin MICs $\geq 8 \mu\text{g mL}^{-1}$) have at least two mutations within target genes and show enhanced efflux (Everett *et al.*, 1996). Everett *et al.* (1996) inferred that that high-level resistant strains containing multiple mutations are unlikely selected in a single step within a host organism.

Those which acquire the right combination of mutations before becoming nonviable are able to resume growth. Studies are in progress to examine whether antibiotic resistance mutations can arise via such a process. The fact is that the low selective pressure allow single mutants and continued selective pressure or a new antibiotic challenge then favors those progeny containing further mutations (Alessiani *et al.*, 2009; Aparicio *et al.*, 1999). The relationship between ciprofloxacin MICs and alterations to the QRDR has been reported in other studies on clinical isolates of *E. coli*. The study of Liu *et al.* (2012a, b) demonstrated that the number of mutations in QRDRs of *gyrA* and/or *parC* was significantly associated with the MICs for quinolones ($p < 0.01$). The resistance rates of ciprofloxacin, enrofloxacin and nalidixic acid in PMQR-positive isolates were significantly higher than those in PMQR-negative isolates, respectively ($p < 0.05$). And the prevalence of *oqxAB* had significant Spearman correlation coefficients in relation to the MICs of all the four tested quinolones ($p < 0.01$) (Liu *et al.*, 2012a, b).

The occurrence of *gyrA* mutations at positions corresponding to amino acid residues 83 and 87 and similarly, the occurrence of *parC* mutations corresponding to residues 80 and 84 are in agreement with data reported in other studies on quinolone-resistant clinical isolates (Karczmarczyk *et al.*, 2011; Sun *et al.*, 2012). In particular, Ser83 to Leu and Asp87 to Asn substitutions in *gyrA* were commonly reported by other research and ubiquitous in the isolates studied here. In this study, an amino acid replacement in the QRDR of *gyrA* (Ser-83→Leu) was predicted for all the nalidixic acid-resistant isolates. When MICs of nalidixic acid of $> 256 \mu\text{g mL}^{-1}$ and MICs of ciprofloxacin ranging from 4 to $> 32 \mu\text{g mL}^{-1}$, several mutations were identified in genes coding for quinolone target enzymes (3-5 mutations per strain). All isolates harbored *gyrA* amino acid substitutions at positions 83 and 87 (Karczmarczyk *et al.*, 2011). About 23 isolates studied here with nalidixic acid MIC $\geq 128 \mu\text{g mL}^{-1}$ and resistant to ciprofloxacin, possessed double point mutations in *gyrA*, Ser-83→Leu and Asp-87→Asn. It was predicted the replacements of

Ser-83→Leu and Asp-87→Asn in *gyrA* of ciprofloxacin-resistant isolates was the principal replacement (23 of 23 isolates; 100%) while other substitutions were rare. Polymorphisms within the *gyrB* sequence have rarely been reported in quinolone-resistant isolates. Substitutions at residue positions 389, 426, 447 and 464 were earlier described (Couzinet *et al.*, 2005; Moon *et al.*, 2010; Ouabdesselam *et al.*, 1995).

In one study, the Ser492-to-Asn substitution identified in *gyrB* of two isolates is localized outside the putative QRDR. In *gyrB*, researchers found changes of Asp-96 to Glu in 1 isolate, Ala-97 to Pro in 1 isolate and to Phe in 1 isolate and Ser-491 to Asn in 1 isolate. It is difficult to conclude the correlation between the mutation of *gyrB* with MIC values for ciprofloxacin and the various mutation simultaneously possessed in *gyrA* and *parC*. The amino acid sequences in the QRDR of *parC* showed a high frequency of replacement of Ser-80 to Ile (22 isolates) or Arg (1 isolates) while other replacements were rare. Moon *et al.* (2010) detected a new mutation in topoisomerase IV genes and found all ciprofloxacin-resistant *E. coli* isolates carried double mutations in *gyrA* and at least a single mutation in *parC* some isolates also carried a single mutation in *parE*. The most common mutations were S83L and D87N in *gyrA*, S80I in *parC* and S458A in *parE* which accounted for 25% of isolates. Double mutations in *parC* and a combination of single mutations in *parC* and *parE* significantly increased the MIC values of fluoroquinolones (Moon *et al.*, 2010).

Plasmid-mediated *qnr* and *aac(6)-Ib-cr* genes confer reduced quinolone susceptibility, facilitating the selection of chromosomal mutations that confer high-level resistance (Jouini *et al.*, 2010; Shin *et al.*, 2009; Warburg *et al.*, 2009). *Qnr* and *aac(6)-Ib-cr* have therefore been hypothesized as potential contributors to the increase in prevalence of quinolone resistance among gram-negative bacteria. Among ciprofloxacin-resistant strains studied, it was found that seven isolates carried *qnrS* gene and three carried *aac(6)-Ib-cr* gene.

CONCLUSION

Thus, it was concluded that the *qnrS* and *aac(6)-Ib-cr* genes were rare in APEC and showed little significant relation to the high-level quinolone in APEC.

ACKNOWLEDGEMENTS

This research was supported by Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT), IRT0978.

REFERENCES

- Alessiani, A., E. di Giannatale, M. Perilli, C. Forcella, G. Amicosante and K. Zilli, 2009. Preliminary investigations into fluoroquinolone resistance in *Escherichia coli* strains resistant to nalidixic acid isolated from animal faeces. *Vet. Ital.*, 45: 521-527.
- Antao, E.M., C. Ewers, D. Gurlebeck, R. Preisinger, T. Homeier, G. Li and L.H. Wieler, 2009. Signature-tagged mutagenesis in a chicken infection model leads to the identification of a novel avian pathogenic *Escherichia coli* fimbrial adhesin. *PLoS One*, Vol. 4. 10.1371/journal.pone.0007796.
- Aparicio, J.R., J. Such, S. Pascual, A. Arroyo and J. Plazas *et al.*, 1999. Development of quinolone-resistant strains of *Escherichia coli* in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: Clinical consequences. *J. Hepatol.*, 31: 277-283.
- Boyd, L.B., R.L. Atmar, G.L. Randall, R.J. Hamill, D. Steffen and L. Zechiedrich, 2008. Increased fluoroquinolone resistance with time in *Escherichia coli* from >17,000 patients at a large county hospital as a function of culture site, age, sex and location. *BMC Infect. Dis.*, Vol. 8. 10.1186/1471-2334-8-4.
- Couzinet, S., J. Yugueros, C. Barras, N. Visomblin and P. Francois *et al.*, 2005. Evaluation of a high-density oligonucleotide array for characterization of *griA*, *griB*, *gyrA* and *gyrB* mutations in fluoroquinolone resistant *Staphylococcus aureus* isolates. *J. Microbiol. Methods*, 60: 275-279.
- Dho-Moulin, M. and J.M. Fairbrother, 1999. Avian pathogenic *Escherichia coli* (APEC). *Vet. Res.*, 30: 299-316.
- Everett, M.J., Y.F. Jin, V. Ricci and L.J. Piddock, 1996. Contributions of individual mechanisms to fluoroquinolone resistance in 36 *Escherichia coli* strains isolated from humans and animals. *Antimicrob. Agents Chemother.*, 40: 2380-2386.
- Ewers, C., G. Li, H. Wilking, S. Kiessling and K. Alt *et al.*, 2007. Avian pathogenic, uropathogenic and newborn meningitis-causing *Escherichia coli*: How closely related are they?. *Int. J. Med. Microbiol.*, 297: 163-176.
- George, A.J., K.E. Walsh, D.M. Mills, V.J. Walker, O.H. Herin, A. Robicsek and D.C. Hooper 2006. *qnrB*, another plasmid mediated gene for quinolone resistance. *Antimicrob. Agents Chemother.*, 50: 1178-1182.
- Gomis, S., L. Babiuk, D.L. Godson, B. Allan and T. Thrush *et al.*, 2003. Protection of chickens against *Escherichia coli* infections by DNA containing CpG motifs. *Infect. Immun.*, 71: 857-863.
- Gross, W.B., 1994. Diseases Due to *Escherichia coli* in Poultry. In: *Escherichia coli* in Domesticated Animals and Humans, Gyles, C.L. (Ed.). CAB International, Wallingford, UK., ISBN: 0-85198-921-7, pp: 237-259.
- Jeong, Y.W., T.E. Kim, J.H. Kim and H.J. Kwon, 2012. Pathotyping avian pathogenic *Escherichia coli* strains in Korea. *J. Vet. Sci.*, 13: 145-152.
- Johnson, J.R., A. Gajewski, A.J. Lesse and T.A. Russo, 2003. Extraintestinal pathogenic *Escherichia coli* as a cause of invasive nonurinary infections. *J. Clin. Microbiol.*, 41: 5798-5802.
- Jouini, A., K. Ben Slama, L. Vinue, E. Ruiz and Y. Saenz *et al.*, 2010. Detection of unrelated *Escherichia coli* strains harboring genes of CTX-M-15, OXA-1 and AAC(6)-Ib-cr enzymes in a Tunisian hospital and characterization of their integrons and virulence factors. *J. Chemother.*, 22: 318-323.
- Karaca, Y., N. Coplu, A. Gozalan, O. Oncul, B.E. Cital and B. Esen, 2005. Co-trimoxazole and quinolone resistance in *Escherichia coli* isolated from urinary tract infections over the last 10 years. *Int. J. Antimicrob. Agents*, 26: 75-77.
- Karczmarczyk, M., M. Martins, T. Quinn, N. Leonard and S. Fanning, 2011. Mechanisms of fluoroquinolone resistance in *Escherichia coli* isolates from food-producing animals. *Applied Environ. Microbiol.*, 77: 7113-7120.
- Kariyawasam, S., J.A. Scaccianoce and L.K. Nolan, 2007. Common and specific genomic sequences of avian and human extraintestinal pathogenic *Escherichia coli* as determined by genomic subtractive hybridization. *BMC Microbiol.*, Vol. 7. 10.1186/1471-2180-7-81.
- Li, Z., T. Deguchi, M. Yasuda, T. Kawamura and E. Kanematsu *et al.*, 1998. Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of *Staphylococcus epidermidis*. *Antimicrob. Agents Chemother.*, 42: 3293-3295.
- Liu, B.T., X.P. Liao, S.D. Liao, N. Sun and M.J. Zhang *et al.*, 2012a. Plasmid-mediated quinolone resistance determinant *qepA1* and extended-spectrum β -lactamase gene *blaCTX-M-14* co-located on the same plasmid in two *Escherichia coli* strains from China. *J. Med. Microbiol.*, 61: 603-605.
- Liu, B.T., X.P. Liao, S.S. Yang, X.M. Wang and L.L. Li *et al.*, 2012b. Detection of mutations in *gyrA* and *parC* genes in *Escherichia coli* isolates carrying plasmid-mediated quinolone resistance genes from diseased food-producing animals. *J. Med. Microbiol.*, 10.1099/jmm.0.043307-0.

- Lo, W.T., W.J. Lin, T.S. Chiueh, S.Y. Lee, C.C. Wang and J.J. Lu, 2011. Changing trends in antimicrobial resistance of major bacterial pathogens, 1985-2005: A study from a medical center in northern Taiwan. *J. Microbiol. Immunol. Infect.*, 44: 131-138.
- Martinez-Martinez, L., A. Pascual and G.A. Jacoby, 1998. Quinolone resistance from a transferable plasmid. *Lancet*, 351: 797-799.
- McPeake, S.J.W., J.A. Smyth and H.J. Ball, 2005. Characterization of Avian Pathogenic *Escherichia coli* (APEC) associated with colisepticaemia compared to faecal isolates from healthy birds. *Vet. Microbiol.*, 110: 245-253.
- Moon, D.C., S.Y. Seol, M. Gurung, J.S. Jin and C.H. Choi *et al.*, 2010. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in *Escherichia coli* isolates. *Int. J. Antimicrob. Agents*, 35: 76-79.
- Noguera, O., N. Lopez-Riquelme, J.C. Rodriguez, S. Belda and A. Galiana *et al.*, 2011. Fluoroquinolone resistance in *Escherichia coli* and *Klebsiella pneumonia* over 18 years: Effect of different systems for eliminating duplicates. *J. Antimicrob. Chemother.*, 66: 2182-2184.
- Obeng, A.S., H. Rickard, O. Ndi, M. Sexton and M. Barton, 2012. Antibiotic resistance, phylogenetic grouping and virulence potential of *Escherichia coli* isolated from the faeces of intensively farmed and free range poultry. *Vet. Microbiol.*, 154: 305-315.
- Orskov, F., and I. Orskov, 1990. The serology of capsular antigens. *Current Topics Microbiol. Immunol.*, 150: 43-63.
- Ouabdessalam, S., D.C. Hooper, J. Tankovic and C.J. Soussy, 1995. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of *Escherichia coli* by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. *Antimicrob. Agents Chemother.*, 39: 1667-1670.
- Shaheen, B.W., D.M. Boothe, O.A. Oyarzabal, C. Wang and C.M. Johnson, 2011. Evaluation of the contribution of gyrA mutation and efflux pumps to fluoroquinolone and multidrug resistance in pathogenic *Escherichia coli* isolates from dogs and cats. *Am. J. Vet. Res.*, 72: 25-32.
- Shin, S.Y., K.C. Kwon, J.W. Park, J.H. Song and Y.H. Ko *et al.*, 2009. Characteristics of aac(6')-Ib-cr gene in extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumonia* isolated from Chungnam area. *Korean J. Lab. Med.*, 29: 541-550.
- Sorlozano, A., J. Gutierrez, A. Jimenez, J. de Dios Luna, and J.L. Martinez, 2007. Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-beta-lactamase-producing *Escherichia coli* isolates. *J. Clin. Microbiol.*, 45: 2740-2742.
- Sun, J., J. Hu, H. Peng, J. Shi and Z. Dong, 2012. Molecular and physiological characterization of fluoroquinolone resistance in relation to uropathogenicity among *Escherichia coli* isolates isolated from Wenyu River, China. *Chemosphere*, 87: 37-42.
- Swick, M.C., S.K. Morgan-Linnell, K.M. Carlson and L. Zechiedrich, 2011. Expression of multidrug efflux pump genes acrAB-tolC, mdfA, and norE in *Escherichia coli* clinical isolates as a function of fluoroquinolone and multidrug resistance. *Antimicrob. Agents Chemother.*, 55: 921-924.
- Vasilaki, O., E. Ntokou, A. Ikonomidis, D. Sofianou and F. Frantidou *et al.*, 2008. Emergence of the plasmid-mediated quinolone resistance gene *qnrS 1* in *Escherichia coli* isolate in Greece. *Antimicrob. Agents Chemother.*, 52: 2996-2997.
- Vila, J., J. Ruiz, P. Goni and M.T. de Anta, 1996. Detection of mutations in parC in quinolone-resistant clinical isolates of *Escherichia coli*. *Antimicrob. Agents Chemother.*, 40: 491-493.
- Wang, X.M., X.P. Liao, W.J. Zhang, H.X. Jiang and J. Sun *et al.*, 2010. Prevalence of serogroups, virulence genotypes, antimicrobial resistance, and phylogenetic background of avian pathogenic *Escherichia coli* in south of China. *Foodborne Pathog. Dis.*, 7: 1099-1106.
- Warburg, G., M. Korem, A. Robicsek, D. Engelstein, A.E. Moses, C. Block and J. Strahilevitz, 2009. Changes in aac(6')-Ib-cr prevalence and fluoroquinolone resistance in nosocomial isolates of *Escherichia coli* collected from 1991 through 2005. *Antimicrob. Agents Chemother.*, 53: 1268-1270.
- Yasufuku, T., K. Shigemura, T. Shirakawa, M. Matsumoto and Y. Nakano *et al.*, 2011. Correlation of overexpression of efflux pump genes with antibiotic resistance in *Escherichia coli* strains clinically isolated from urinary tract infection patients. *J. Clin. Microbiol.*, 49: 189-194.
- Yoshida, H., T. Kojima, J. Yamagishi and S. Nakamura, 1988. Quinolone-resistant mutations of the *gyrA* gene of *Escherichia coli*. *Mol. Gen. Genet.*, 211: 1-7.
- Zhao, S., J.J. Maurer, S. Hubert, J.F. de Villena and P.F. McDermott *et al.*, 2005. Antimicrobial susceptibility and molecular characterization of avian pathogenic *Escherichia coli* isolates. *Vet. Microbiol.*, 107: 215-224.